Glimpure M 2mg/500mg Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg in a sustained-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet, exercise, and monotherapy with either agent alone. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The sustained-release formulation allows for a gradual release of the active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Glimpure M should be used as part of a comprehensive diabetes management plan including diet and exercise. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Regular monitoring of blood glucose, renal function, and liver function is recommended during therapy. Dose adjustments may be necessary based on clinical response and tolerability. Patients should be counseled on recognizing signs of hypoglycemia and the importance of adherence to prescribed therapy.